ACTIVATION OF C-MYC, C-NEU AND INT-2 ONCOGENES IN THE TRANSFORMATION OF THE HUMAN BREAST EPITHELIAL-CELL LINE MCF-10F TREATED WITH CHEMICALCARCINOGENS IN-VITRO
Pl. Zhang et al., ACTIVATION OF C-MYC, C-NEU AND INT-2 ONCOGENES IN THE TRANSFORMATION OF THE HUMAN BREAST EPITHELIAL-CELL LINE MCF-10F TREATED WITH CHEMICALCARCINOGENS IN-VITRO, International journal of oncology, 6(5), 1995, pp. 963-968
Genetic alterations of the c-myc, c-neu and int-2 oncogenes have been
reported in human breast cancer. In order to determine if these oncoge
nes are activated at different stages of breast cancer progression, we
are using an in vitro system in which human breast epithelial cells (
MCF-10F) have been transformed with benzo(a)pyrene(BP) or dimethylbenz
(a)anthracene (DMBA). DMBA-treated cells gave rise to clones D3 and D3
-1, BP-treated cells gave rise to clones BP1 and BP1-E. BP1-E cell lin
e, derived from BP1 cell line, was tumorigenic in SCID mice. Southern
blot analysis detected gene amplification and rearrangement of the int
-2 oncogene in BP1 and BP1-E cells, but no changes were detected in D3
and D3-1 cells. Amplification of c-neu gene was only observed in BP1
and BP1-E cell lines. Neither amplification nor rearrangement was dete
cted for the c-myc gene. At the transcriptional level, Northern blot a
nalysis showed that int-2 mRNA was increased 1.5, 1.8, 1.3 and 2.0-fol
d in the BP1, BP1-E, D3 and D3-1 cell lines respectively. c-neu mRNA w
as increased 8.0-fold in BP1 and BP-1E cells and c-myc mRNA was increa
sed 1.5-fold in D3 cells, but no changes were detected in the other ce
ll lines. The data indicate that BP treatment induces changes both at
the genomic and transcriptional level. However, none of the difference
s explain the tumorigenic properties of the BP1-E cell line. DMBA trea
tment induces changes that are only reflected at transcriptional level
for the two oncogenes studied. Whereas none of these oncogenes can be
considered the driving force in the expression of the tumorigenic phe
notype, the interaction among them or with other oncogenes in the expr
ession of the transformation phenotype cannot be ruled out.